Paper41979035
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.
Azad AA and 10 others. Future Oncol, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01. Papers, record 41979035. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41979035
- Disease
- prostate cancer757 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Androgen Receptor Antagonists | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Prostatic Neoplasms | Major topic |
| Humans | |
| Male | |
| Benzamides | |
| Double-Blind Method | |
| Poly(ADP-ribose) Polymerase Inhibitors | |
| Receptors, Androgen |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06120491 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Derived from the trial | Yes |
Source ClinicalTrials.gov
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31157964 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31157964 | PubMed |
| 2 | 26903579 | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/26903579 | PubMed |
| 3 | 33993099 | Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease. | Transl Oncol | 2021 | https://conductscience.org/library/papers/33993099 | PubMed |
| 4 | 40683290 | Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. | Lancet | 2025 | https://conductscience.org/library/papers/40683290 | PubMed |
| 5 | 34328216 | Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: A population-based registry study. | Cancer | 2021 | https://conductscience.org/library/papers/34328216 | PubMed |
| 6 | 32169995 | Long-term Trends in Prostate Cancer Incidence by Stage at Diagnosis in Japan Using the Multiple Imputation Approach, 1993-2014. | Cancer Epidemiol Biomarkers Prev | 2020 | https://conductscience.org/library/papers/32169995 | PubMed |
| 7 | 41064809 | Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair. | NAR Cancer | 2025 | https://conductscience.org/library/papers/41064809 | PubMed |
| 8 | 35929986 | Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35929986 | PubMed |
| 9 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 10 | 28851861 | Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. | Nat Commun | 2017 | https://conductscience.org/library/papers/28851861 | PubMed |
| 11 | 27989354 | Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. | Eur Urol | 2017 | https://conductscience.org/library/papers/27989354 | PubMed |
| 12 | 41057655 | Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. | Nat Med | 2025 | https://conductscience.org/library/papers/41057655 | PubMed |
| 13 | 32955174 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32955174 | PubMed |
| 14 | 41591905 | Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41591905 | PubMed |
| 15 | 34759656 | High rates of advanced prostate cancer in the Middle East: Analysis from a tertiary care center. | Urol Ann | 2021 | https://conductscience.org/library/papers/34759656 | PubMed |
| 16 | 37963304 | Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/37963304 | PubMed |
| 17 | 25601341 | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25601341 | PubMed |
| 18 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 19 | 28536297 | Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. | Sci Signal | 2017 | https://conductscience.org/library/papers/28536297 | PubMed |
| 20 | 29367197 | Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. | Cancer Discov | 2018 | https://conductscience.org/library/papers/29367197 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42568603 | From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors. | Front Oncol | 2026 | https://conductscience.org/library/papers/42568603 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AR | 367 | PubTator's text mining | https://conductscience.org/library/genes/367 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| SARUPARIB | CHEMBL5095220 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL5095220 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41979035
GET https://conductscience.org/api/papers/v1/41979035/references?page=2